GR1803 injection versus daratumumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 3 randomized interventional comparison assigns participants to receive either GR1803 injection or daratumumab plus pomalidomide and dexamethasone (DPd). Eligible participants must have 1–3 prior lines of antimyeloma therapy including a proteasome inhibitor and lenalidomide (patients with only one prior line must be lenalidomide-refractory), measurable disease, and ECOG performance status 0–2. Disease response and progression are followed using standard IMWG criteria while participants receive the assigned regimen. The study is sponsored by Genrix (Shanghai) Biopharmaceutical and is recruiting at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences in Tianjin, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have an eastern cooperative oncology group (ECOG) performance status score of 0, 1, or 2 at screening and baseline.
* Diagnosed as multiple myeloma according to the diagnostic criteria of the International Myeloma Working Group (IMWG) diagnostic criteria.
* Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide; a. participants who have received only 1 line of prior line of antimyeloma therapy must be lenalidomide refractory. Stable disease or progression on or within 60 days of the last dose of lenalidomide given as maintenance will meet this criterion.
* Documented evidence of progressive or stable disease based on investigator's determination of response by IMWG criteria on or after their last regimen.
* Measurable disease at screening and baseline as defined by any of the following: 1) serum M-protein level greater than or equal to (\>=) 5 gram per liter (g/L); or 2) urine M-protein level \>=200 milligrams (mg)/24 hours; or 3) serum immunoglobulin free light chain \>=100 mg/L and abnormal serum immunoglobulin kappa lambda free light chain ratio.
* Have clinical laboratory values within the specified range.
* Have an understanding of and comply with the clinical trial protocol requirements, voluntarily participate in the clinical trial, and sign the informed consent form.

Exclusion Criteria:

* Plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or amyloidosis (including primary and secondary).
* History or clinical signs of central nervous system involvement or meningeal involvement of multiple myeloma .
* Received any prior B cell maturation antigen (BCMA)-directed therapy.
* Has disease that is considered refractory or intolerant to an anti-cluster of differentiation 38 (CD38) targeted therapy or Pomalidomide.
* Prior antitumor therapy, within 21 days (PI 、IMiDs or radiotherapy within 14 days, clinical trial vaccine within 28 days, Gene modified adoptive cell therapy within 3 months, allogeneic stem cell transplantation within 6 months, autologous stem cell transplantation within 12 weeks) prior to first dose of study drug.
* Received a cumulative dose of corticosteroids equivalent to \>=140 mg of prednisone within 14 days prior to first dose of study drug.
* Grade \>= 2 peripheral neuropathy at screening.
* History of Guillain Barre Syndrome (GBS) or variant GBS.
* The following medical conditions: active infecion, human immunodeficiency virus (HIV) infection, hepatitis B or C infection, Syphilis infection, thromboembolic events or cerebrovascular events less than or equal to (\<=) 6 m, seizure attacks less than or equal to (\<=) 6 m.
* Active malignancies other than relapsed/refractory multiple myeloma within 3 years prior to screening.
* Active autoimmune disease or history of autoimmune disease.
* Received a live, attenuated vaccine within 4 weeks before first dose of study drug.
* Have major surgery within 2 weeks before first dose of study drug.
* Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients.
* Pregnant, lactating female.

Where it's running

• Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
  Tianjin, China Recruiting

Study contacts

• Study coordinator: Gang An
• Email: angang@ihcams.ac.cn
• Phone: 13502181109

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• Maintaining myeloma with less frequent daratumumab plus lenalidomide

  This phase 2 study tests a reduced-dosing schedule of daratumumab with lenalidomide to maintain remission in adults with multiple myeloma after stem cell transplant.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07485647

• Belantamab Mafodotin or Daratumumab with VRd for Newly Diagnosed High-Risk Myeloma

  This study tests whether belantamab mafodotin plus standard multiple myeloma drugs works better than daratumumab plus the same drugs for people newly diagnosed and ineligible for transplant.

  Recruiting Phase 3 PrECOG, LLC. · La Crosse, Wisconsin · NCT07285239

• Etentamig plus daratumumab versus daratumumab‑lenalidomide‑dexamethasone for newly diagnosed multiple myeloma in patients not eligible for transplant

  This trial will test whether adding the investigational drug etentamig to daratumumab helps control disease and is safe in adults newly diagnosed with multiple myeloma who cannot have a transplant.

  Recruiting at 49 sites Phase 2/3 AbbVie · Scottsdale, Arizona and 48 other locations · NCT07095452

• Linvoseltamab versus standard daratumumab‑lenalidomide‑dexamethasone for adults with newly diagnosed, transplant‑ineligible multiple myeloma

  This trial tests whether linvoseltamab works better or is safer than the standard daratumumab‑lenalidomide‑dexamethasone combination in adults newly diagnosed with multiple myeloma who are not eligible for transplant.

  Recruiting at 59 sites Phase 3 European Myeloma Network B.V. · Adelaide and 58 other locations · NCT06932562

• Combining JNJ-79635322 with Daratumumab or Pomalidomide for Multiple Myeloma Treatment

  This study is testing a new drug called JNJ-79635322 combined with either daratumumab or pomalidomide to see how safe and effective it is for people with multiple myeloma.

  Recruiting at 16 sites Phase 1 Janssen Research & Development, LLC · Denver, Colorado and 15 other locations · NCT06768489

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.